IL-31 Reporter HEK 293 Cells
Product | Unit size | Cat. code | Docs. | Qty. | Price | |
---|---|---|---|---|---|---|
HEK-Blue™ IL-31 Cells Human IL-31 Reporter Cells |
Show product |
3-7 x 10e6 cells |
hkb-il31
|
|
||
HEK-Blue™ IL-31 vial Additional cell vial |
Show product |
3-7 x 10e6 cells |
hkb-il31-av
|
Notification: Reference #hkb-il31-av can only be ordered together with reference #hkb-il31.
Interleukin-31 Reporter Cells
Signaling pathway in HEK-Blue™ IL-31 cells
HEK-Blue™ IL-31 cells were engineered from the human embryonic kidney HEK 293 cell line to detect bioactive interleukin-31 (IL-31) by monitoring the activation of the JAK/STAT5 pathway. They can also be used for screening antibodies or small molecule inhibitors targeting the IL-31 pathway.
IL-31 is a secreted cytokine that seems to be strongly involved in chronic inflammation in different skin diseases, including atopic dermatitis and allergic contact dermatitis [1].
Cell line description
HEK-Blue™ IL-31 cells were generated by stable transfection with the genes encoding for the human IL-31 receptor (IL-31Rα and human OSMRβ (oncostatin M receptor β) chains), STAT5b, and a STAT5-inducible secreted embryonic alkaline phosphatase (SEAP) reporter. The binding of IL-31 to its receptor triggers a signaling cascade leading to the activation of STAT5 and the subsequent production of SEAP. This can be readily assessed in the supernatant using QUANTI-Blue™ Solution, a SEAP detection reagent.
HEK-Blue™ IL-31 cells detect human IL-31 but not murine IL-31 (see figures). Of note, they also respond to hIFN-γ. However, they do not respond to hIFN-α and hIFN-β (see figures).
Key features
- Fully functional IL-31 signaling pathway
- Readily assessable STAT5-inducible SEAP reporter activity
- Strong response to human (h) IL-31
- No response to mouse (m) IL-31
Applications
- Detection and quantification of hIL-31 activity
- Screening of anti-IL-31 and anti-IL-31 receptor antibodies
- Screening of small molecule inhibitors of the IL-31 pathway
Reference:
1. Datsi A, et al., 2021. Interleukin-31: The "itchy" cytokine in inflammation and therapy. Allergy. 76: 2982-2997.
Back to the topSpecifications
Antibiotic resistance: Blasticidin, Hygromycin B, Zeocin®
Growth medium: DMEM, 4.5 g/l glucose, 2-4 mM L-glutamine, 10% (v/v) fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, 100 μg/ml Normocin®
Specificity: Detects human IL-31
Detection range:
- Detection range for human IL-31: 1 pg/ml - 1 ng/ml
Quality Control:
- The expression of human IL-31Rα and OSMRβ is assessed by flow cytometry.
- SEAP reporter activity in response to IL-31 is validated using functional assays.
- The stability for 20 passages following thawing is confirmed.
- These cells are tested for mycoplasma contamination.
This product is covered by a Limited Use License (See Terms and Conditions).
Back to the topContents
- 1 vial containing 3-7 x 106 cells
- 1 ml Normocin® (50 mg/ml)
- 2 x 1 ml of HEK-Blue Selection (250X)
- 1 ml of QB reagent and 1 ml of QB buffer (sufficient to prepare 100 ml of QUANTI-Blue™ Solution, a SEAP detection reagent).
Shipped on dry ice (Europe, USA, Canada, and some areas in Asia)
Back to the topDetails
The cytokine interleukin 31 (IL-31) belongs to the Type I/II cytokine receptor family, and more specifically to the IL-6/gp130 family. IL-31 signals through a heterodimeric receptor comprised of the gp130-like subunit IL-31Rα and the OSMRb (oncostatin M receptor) subunit. The binding of IL-31 to its receptor triggers activation of the JAK/STAT, Akt/PI3K, and MAPK signaling pathways [1,2]. IL-31 receptor complex is expressed in epithelial, neuronal as well as immune cells. Little is known about the physiological function of IL-31. It is mainly secreted by IL-4-activated T cells, thereby contributing to Th2-weighted inflammation [1,2]. Several reports indicate that IL-31 is implicated in disorders such as atopic dermatitis, asthma, and inflammatory bowel disease [1,2]. Of note, IL-31 appears a critical cytokine involved in neuro-immune communication, through the mediation of inflammatory itch [1,2]. Targeting the IL-31 pathway is a promising therapeutic option for dermatologic and non-dermatologic diseases with enhanced IL-31 expression [1,2].
References:
1. Bagci I.S. and Ruzicka, T., 2018. IL-31: A new player in dermatology and beyond. J. Allergy Clin Immunol. 141(3):858-866.
2. Datsi A., et al., 2021. Interleukin-31: The “itchy” cytokine in inflammation and therapy. Allergy. 76:2982-97.